证券代码：600833 证券简称：第一医药 公告编号：临 2023-029 上海第一医药股份有限公司 关于董事辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 上海第一医药股份有限公司（以下简称"公司"）董事会近日收到公司董事史小龙 先生的书面辞任报告，史小龙先生因工作原因，申请辞去公司第十届董事会董事及董事 会薪酬与考核委员会委员等职务。根据《公司法》《公司章程》的有关规定，史小龙先 生的辞任不会导致公司董事会低于法定最低人数，辞任报告自送达公司董事会之日起生 效。 辞任后，史小龙先生不再担任公司任何职务。截至本公告日，史小龙先生未持有公 司股份，其工作已进行妥善交接，不会影响公司董事会正常运作，不会影响公司正常经 营。 史小龙先生在任职期间勤勉尽责、恪尽职守。公司董事会对史小龙先生在任职期间 对公司所做的贡献表示衷心感谢！ 特此公告。 上海第一医药股份有限公司董事会 2023 年 8 月 12 日 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 证券代码：600833 证券简称：第一医药 公告编号：临 2023-030 上海第一医药股份有限公司 第十届董事会第十二次（临时）会议决议公告 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十届董事会第十二次（临时）会 议于 2023 年 8 月 4 日以邮件方式通知，于 2023 年 8 月 11 日以通讯方式召开。本次会 议由董事长孙伟先生召集并主持。本次会议应参加表决董事为 8 名，委托 0 名，实际参 加表决董事 8 名。会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于补选第十届董事会非独立董事的议案》 补选姚军先生为公司第十届董事会非独立董事，任期自股东大会审议通过之日起至 公司第十届董事会届满之日止。 具体内容详见同日刊载于上海证券交易所网站 http://www.sse.com.cn《上 ...

上海第一医药股份有限公司独立董事 关于公司第十届董事会第十二次（临时）会议审议事项的独立意见 根据中国证券监督管理委员会颁布的《上市公司独立董事规则》《公司章程》及公司 《独立董事制度》的有关规定，我们作为上海第一医药股份有限公司第十届董事会独立 董事，现就公司第十届董事会第十二次（临时）会议审议事项发表如下意见： 一、关于补选第十届董事会董事的独立意见 经仔细审阅公司董事会提交的公司董事候选人的个人履历等相关资料，基于我们个 人的客观、独立的判断，我们认为，姚军先生具备相关专业知识和工作经验，符合公司 对董事的任职要求，且不存在《中华人民共和国公司法》《上海证券交易所股票上市规 则》等法律法规和《公司章程》规定不得担任公司董事的情形。 公司补选姚军先生为公司董事的程序符合有关法律法规和《公司章程》的规定。综 上，我们同意姚军先生为公司第十届董事会非独立董事候选人，任期自股东大会审议通 过之日起至第十届董事会届满为止，并同意将本议案提交公司股东大会审议。 独立董事签名： CHENG JUNPEI（程俊佩） 经仔细审阅公司董事会提交的公司董事候选人的个人履历等相关资料，基于我们个 人的客观、独立的判断，我们认为 ...

上海第一医药股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日召开第十届 董事会第十二次（临时）会议，审议通过了《关于补选第十届董事会非独立董事的议案》。 史小龙先生因工作原因辞去公司第十届董事会董事、董事会薪酬与考核委员会委员 等职务。根据《公司章程》的规定，经公司股东提名及董事会提名委员会资格审查通过， 董事会同意提名姚军先生（简历附后）为公司第十届董事会非独立董事候选人，任期自 股东大会审议通过之日起至第十届董事会届满之日止。 公司独立董事对补选董事的事项发表了同意的独立意见： 经仔细审阅公司董事会提交的公司董事候选人的个人履历等相关资料，基于我们个 人的客观、独立的判断，我们认为，姚军先生具备相关专业知识和工作经验，符合公司 对董事的任职要求，且不存在《中华人民共和国公司法》《上海证券交易所股票上市规 则》等法律法规和《公司章程》规定不得担任公司董事的情形。公司补选姚军先生为公 司董事的程序符合有关法律法规和《公司章程》的规定。综上，我们同意姚军先生为公 司第十届董事会非独立董事候选人，任期自股东大会审议通过之日起至第十届董事会届 满为止，并同意将本事项提交公司股东大会审议。 特此公告 ...

上海第一医药股份有限公司（以下简称"公司"）监事会近日收到公司职工监事徐 岚女士的书面辞任报告，徐岚女士因工作原因，申请辞去公司第十届监事会职工监事职 务。徐岚女士辞任后，公司监事会人数将少于法定最低人数，故其辞任自公司选举产生 新的职工监事后开始生效。截至本公告日，徐岚女士未持有公司股份，徐岚女士在任职 期间勤勉尽责、恪尽职守，公司监事会对徐岚女士在任职期间对公司所做的贡献表示衷 心感谢！ 证券代码：600833 证券简称：第一医药 公告编号：临 2023-028 上海第一医药股份有限公司 关于变更职工监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 附胡良玉先生简历： 胡良玉，男，43 岁，中国国籍，无境外永久居留权，大学本科，高级政工师，中 共党员。曾任上海华联商厦党群办团委干事、团委书记，上海百联集团股份有限公司 团委书记，百联集团有限公司团委副书记、团委书记等职务。现任上海第一医药股份 有限公司党委副书记、纪委书记、工会负责人。 截至本公告披露日，胡良玉先生未持有公司股票，其与公司控股股东及实际控制人、 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2023-020 上海第一医药股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 11 日(星期四) 至 05 月 17 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 shcred@online.sh.cn 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 上海第一医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 1 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 18 日下午 13:00-14:00 举行 2022 年度业绩说明会，就投资者关心的问 题进行交流。 一、说明会类型 会议召开时间：2023 年 05 月 18 日(星期四) 下午 13:00-14:00 会议 召开地点： 上海证券 交易所 上 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 459,099,405.27, representing a year-on-year increase of 17.29%[5] - Net profit attributable to shareholders reached CNY 29,612,934.80, a significant increase of 373.18% compared to the same period last year[5] - The net cash flow from operating activities was CNY 110,910,482.82, reflecting a year-on-year growth of 327.92%[5] - Basic earnings per share (EPS) stood at CNY 0.1327, up by 372.39% year-on-year[5] - The operating profit for Q1 2023 was CNY 13,131,911.76, compared to CNY 8,150,857.93 in Q1 2022, representing a year-over-year increase of 61.5%[17] - The total profit for Q1 2023 reached CNY 38,846,843.85, significantly higher than CNY 8,208,293.96 in Q1 2022, marking a substantial increase[17] - The net profit for Q1 2023 was CNY 29,612,934.80, a significant increase from CNY 6,258,328.50 in Q1 2022, representing a growth of approximately 373%[18] - Total comprehensive income for Q1 2023 was CNY 43,844,285.02, compared to CNY 54,842,713.95 in Q1 2022, indicating a decrease of about 20%[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,098,107,327.86, an increase of 2.89% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 2,098,107,327.86, compared to CNY 2,039,102,174.03 at the end of 2022, indicating a growth of 2.9%[14] - The total liabilities increased to CNY 1,095,584,963.71 as of March 31, 2023, from CNY 1,080,424,094.90 at the end of 2022, reflecting a rise of 1.4%[14] - The total equity attributable to shareholders rose to CNY 995,515,048.26 as of March 31, 2023, compared to CNY 951,670,763.24 at the end of 2022, an increase of 4.6%[14] Cash Flow - Cash and cash equivalents decreased to CNY 388,289,848.26 as of March 31, 2023, from CNY 504,932,742.28 at the end of 2022, a decline of 23.1%[12] - Operating cash flow for Q1 2023 was CNY 110,910,482.82, a turnaround from a negative cash flow of CNY -48,661,494.93 in Q1 2022[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 387,989,848.26, up from CNY 151,071,135.14 in Q1 2022, reflecting an increase of approximately 156%[20] - The company reported a net cash outflow from investing activities of CNY -212,289,848.73 in Q1 2023, compared to CNY -42,102,569.55 in Q1 2022, indicating increased investment activity[20] - The total cash outflow from financing activities in Q1 2023 was CNY 15,052,939.22, compared to CNY 8,487,445.70 in Q1 2022, indicating an increase in financing costs[20] Shareholder Information - The company had a total of 31,656 common shareholders at the end of the reporting period[9] - The largest shareholder, Bailian Group Co., Ltd., held 44.95% of the shares, totaling 100,274,734 shares[9] Other Income and Expenses - The company reported a net other income of CNY 25,817,244.55 in Q1 2023, compared to CNY 105,731.44 in Q1 2022, showing a significant increase[17] - The company incurred tax expenses of CNY 9,233,909.05 in Q1 2023, compared to CNY 1,949,965.46 in Q1 2022, reflecting an increase of about 373%[18] - Other comprehensive income after tax for Q1 2023 was CNY 14,231,350.22, down from CNY 48,584,385.45 in Q1 2022, showing a decrease of approximately 71%[18] Inventory and Costs - The total operating costs for Q1 2023 were CNY 449,236,452.47, up from CNY 383,410,691.60 in Q1 2022, reflecting a growth of 17.2%[17] - Inventory decreased to CNY 326,159,275.61 as of March 31, 2023, from CNY 334,753,732.46 at the end of 2022, a decline of 2.6%[12]

Financial Performance - The company's operating revenue for 2022 reached ¥2,655,908,524.74, representing a year-on-year increase of 89.94%[23] - The net profit attributable to shareholders of the listed company was ¥143,556,293.25, a significant increase of 190.49% compared to the previous year[23] - The net cash flow from operating activities was ¥132,310,966.22, reflecting a year-on-year growth of 261.91%[23] - Basic earnings per share for 2022 were ¥0.64, up 190.91% from ¥0.22 in 2021[25] - The total assets of the company at the end of 2022 amounted to ¥2,039,102,174.03, an increase of 52.80% compared to the previous year[24] - The company reported a net profit of ¥139,891,611.56 after deducting non-recurring gains and losses, marking a 504.38% increase from the previous year[23] - Net profit attributable to shareholders increased by 190.49% year-on-year, primarily due to the increase in operating revenue[26] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 504.38% year-on-year, mainly driven by the increase in operating revenue[26] - Net cash flow from operating activities increased by 261.91% year-on-year, mainly due to increased cash inflow from operating activities resulting from higher operating revenue[26] - Total assets grew by 52.80% year-on-year, primarily due to an increase in working capital matching sales[26] - Basic and diluted earnings per share increased by 190.91% year-on-year, reflecting the growth in net profit attributable to shareholders[26] - Basic earnings per share after deducting non-recurring gains and losses increased by 530.00% year-on-year, driven by the increase in net profit attributable to shareholders after adjustments[26] Dividends and Shareholder Returns - The company proposed a cash dividend of ¥1.95 per 10 shares, totaling ¥43,501,837.67, which accounts for 30.30% of the net profit attributable to shareholders[6] - The company’s total cash dividend amount for the year is 43,501,837.67 RMB, representing 30.30% of the consolidated net profit attributable to ordinary shareholders[167] - The cash dividend per share is set at 0.70 RMB (including tax), based on a total share capital of 223,086,347 shares[164] - The company must distribute at least 30% of the net profit attributable to shareholders as cash dividends if the annual profit is positive and undistributed profits are also positive[163] - The company has a cash dividend policy that emphasizes reasonable returns to investors, ensuring continuity and stability in profit distribution[156] Business Expansion and Operations - In 2022, the company launched a new store model called "Health Station," enhancing service capabilities and optimizing customer flow and sales data[35] - The company opened 30 new stores during the reporting period, including 26 direct-operated and 4 franchised stores, resulting in a 20% increase in the number of outlets in the Shanghai market compared to the end of 2021[36] - The company has rapidly developed cross-border business, collaborating with brand partners for online operations and establishing a "First Pharmacy Cross-Border Purchase" section in stores[35] - The company implemented a store partner system to improve the operational quality and efficiency of existing stores, with pilot stores showing optimization in gross profit and expenses[35] - The company has expanded its store network, including the renovation of the first pharmacy store and the introduction of new service areas such as health testing centers and traditional Chinese medicine clinics[46] - The company opened multiple new stores in Shanghai throughout 2022, with the last store opening in December, contributing to its market expansion strategy[71] Market Trends and Industry Insights - The national retail pharmacy market growth rates from 2018 to 2022 were 6.9%, 5.5%, 3.6%, 2.1%, and 10.2%, with a significant increase in 2022 due to a surge in demand for related drugs and medical devices[37] - The retail chain rate in China reached 57.22% by the end of 2021, an increase of 0.72% from 2020, and significantly up from 34.3% in 2011[38] - The B2C market for pharmaceuticals reached a scale of 25.4 billion yuan in the first half of 2022, with a market share of 12%, up from 5% in the same period of 2020[39] - The average price reduction for negotiated drugs in the new national medical insurance drug list was 61.71%, with a total of 2860 drug categories included[40] - The company ranked 39th in the sales total among reported pharmaceutical retail enterprises in 2021 and 53rd in the comprehensive competitiveness of pharmaceutical retail in 2022[44] Financial Management and Investments - The company reported a significant increase in accounts receivable by 78.20% to ¥237,999,101.33, due to increased sales[64] - The cash flow from financing activities improved by 205.54% to ¥249,148,497.79, reflecting an increase in short-term borrowings[62] - Inventory increased by 56.06% to ¥334,753,732.46, driven by stockpiling for new store openings and related materials[64] - The company reported a 112.25% increase in investment income to ¥4,121,455.93, due to higher dividends from investments[63] - The company has established a performance evaluation system linking management compensation to business performance, ensuring transparency in executive appointments[119] Risk Management and Governance - The company has outlined potential market and operational risks in its management discussion and analysis section[10] - The company is committed to enhancing its internal control and risk management systems to improve operational management and safeguard shareholder interests[121] - The company has compiled 89 internal control regulations to strengthen its governance framework, covering various aspects of business operations and risk management[121] - The company recognizes a talent shortage risk as competition for skilled professionals in the pharmaceutical sector intensifies, impacting future growth and operational efficiency[111] - The company faces risks from industry policy changes, including the impact of "two-invoice system," "GPO," and "volume-based procurement," which may increase cost pressures on pharmaceutical retail operations[109] Employee and Management Structure - The company has a total of 877 employees, with 279 in the parent company and 598 in major subsidiaries[150] - The company has a diverse employee composition, including 503 sales personnel and 151 technical staff[151] - The company has established a strategic committee to oversee long-term planning and market expansion initiatives[146] - The company has implemented a cash dividend policy that emphasizes reasonable returns to investors, ensuring continuity and stability in profit distribution[156] - The company has a training plan for 2022 that includes seven key initiatives aimed at enhancing employee skills and supporting business development[153] Future Outlook and Strategic Initiatives - The company provided guidance for 2023, expecting revenue growth of 12% to 15%, projecting total revenue between 11.2 billion RMB and 11.5 billion RMB[133] - The company plans to implement a new digital marketing strategy, aiming for a 25% increase in online sales by the end of 2023[139] - The company aims to expand its network coverage by filling gaps in underserved areas and increasing density in key regions, targeting a 15-minute service radius[106] - The company is exploring new business opportunities in cross-border health e-commerce to diversify its operations and create additional revenue streams[105] - The company plans to continue opening new retail stores while improving the quality and profitability of existing stores, optimizing procurement conditions to lower costs and enhance retail gross margins[107]

Financial Performance - The company's operating revenue for Q3 2022 reached CNY 831,547,905.95, representing a year-on-year increase of 127.94%[5] - The net profit attributable to shareholders for the same period was CNY 41,371,791.60, showing a significant increase of 313.10% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 41,365,209.82, with a remarkable increase of 2,489.37% compared to the previous year[5] - The company reported a year-to-date net profit growth of 107.24%, reaching CNY 74,535,052.53[5] - Total operating revenue for the first three quarters of 2022 reached CNY 1,779,159,404.97, a significant increase of 78.5% compared to CNY 996,659,724.28 in the same period of 2021[19] - Net profit for the first three quarters of 2022 was CNY 74,535,052.53, representing a 74.0% increase from CNY 35,965,835.31 in the same period of 2021[21] - The company achieved a basic earnings per share of CNY 0.3341 for the first three quarters of 2022, up from CNY 0.1612 in the same period of 2021[21] - The company’s total profit for the first three quarters of 2022 was CNY 97,838,772.47, compared to CNY 47,574,995.32 in the previous year, reflecting a growth of 105.0%[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 2,278,390,062.85, reflecting a growth of 70.73% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 2,278,390,062.85, an increase from RMB 1,334,462,955.15 as of December 31, 2021, reflecting a growth of approximately 70.7%[16] - The company's current assets totaled RMB 1,377,777,932.94, compared to RMB 662,690,371.57 in the previous year, indicating a significant increase of about 107.5%[14] - Total liabilities amounted to RMB 1,424,714,686.92, up from RMB 556,539,381.41, reflecting an increase of around 156.1%[16] - The company's equity attributable to shareholders reached RMB 846,668,060.04, compared to RMB 770,916,257.85, showing an increase of about 9.8%[16] Cash Flow - The cash flow from operating activities for the year-to-date was CNY 53,910,883.57, with a year-on-year increase of 97.35%[6] - The cash flow from operating activities for the first three quarters of 2022 was CNY 53,910,883.57, compared to CNY 27,317,271.41 in the previous year, indicating a growth of 97.5%[24] - Cash and cash equivalents reached RMB 538,749,679.09, up from RMB 262,283,455.11, representing a growth of approximately 105.5%[14] - Cash and cash equivalents at the end of the first three quarters of 2022 totaled CNY 528,269,679.09, an increase from CNY 252,128,485.18 at the end of the same period in 2021[25] Operating Costs and Expenses - Total operating costs for the first three quarters of 2022 were CNY 1,682,834,534.94, up 73.0% from CNY 973,101,755.36 in the previous year[19] - The company’s sales expenses increased to CNY 163,108,890.44 in the first three quarters of 2022, compared to CNY 115,295,095.60 in the same period of 2021, marking an increase of 41.5%[19] - The company reported a tax expense of CNY 23,303,719.94 for the first three quarters of 2022, compared to CNY 11,609,160.01 in the same period of 2021, indicating an increase of 100.0%[21] Business Growth and Strategy - The increase in revenue was primarily driven by the sales growth of pandemic prevention materials and new business models[8] - The company has not disclosed any significant new product developments or market expansion strategies in the current report[13] - The company provided a future outlook with a revenue guidance of 6 billion RMB for the next fiscal year, indicating a growth target of 12%[26] - New product development includes the launch of a telemedicine platform expected to generate an additional 200 million RMB in revenue[26] - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[26] - A strategic acquisition of a local pharmaceutical company was completed, expected to enhance the product portfolio and increase market penetration[26] - Research and development investment increased by 20% year-over-year, totaling 300 million RMB for the current fiscal year[26] - The company aims to improve operational efficiency, targeting a 5% reduction in costs by the end of the fiscal year[26] - Customer satisfaction scores improved by 10% following the implementation of a new service strategy[26] - The company is exploring partnerships with technology firms to enhance digital health solutions, aiming for a pilot launch in Q2 2023[26] User Engagement - User data showed an increase in active users by 15% compared to the previous quarter, reaching 2 million active users[26]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 947.61 million, representing a year-on-year increase of 49.97% compared to RMB 631.86 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was approximately RMB 33.16 million, an increase of 27.79% from RMB 25.95 million in the previous year[18]. - The basic earnings per share for the first half of 2022 was RMB 0.1487, up 27.86% from RMB 0.1163 in the same period last year[18]. - The company experienced a significant increase in net profit after deducting non-recurring gains and losses, which rose by 107.67% to approximately RMB 32.90 million from RMB 15.84 million in the same period last year[18]. - The company achieved a revenue of 947.61 million yuan, representing a year-on-year growth of 49.97%, with main business revenue increasing by 54.48% to 931.60 million yuan[43]. - Net profit attributable to shareholders reached 33.16 million yuan, up 27.79% year-on-year, while the net profit excluding non-recurring gains and losses surged by 107.67% to 32.90 million yuan[44]. Assets and Liabilities - The total assets of the company at the end of the reporting period reached approximately RMB 2.26 billion, a significant increase of 69.13% compared to RMB 1.33 billion at the end of the previous year[18]. - The company's net assets attributable to shareholders increased by 6.87% to approximately RMB 823.91 million from RMB 770.92 million at the end of the previous year[18]. - The total inventory reached ¥817,234,442.05, a 281.00% increase from ¥214,496,533.27, driven by increased stock of pandemic prevention supplies[53]. - Total liabilities rose to CNY 1,426,108,674.79 from CNY 556,539,381.41, marking an increase of around 156%[124]. - The company's total equity reached CNY 830,922,159.02, up from CNY 777,923,573.74, showing a modest increase of about 7%[124]. Cash Flow - The net cash flow from operating activities for the first half of 2022 was negative RMB 293.54 million, a decline of 1,038.20% compared to a positive cash flow of RMB 31.29 million in the same period last year[18]. - The company's cash inflow from operating activities for the first half of 2022 was CNY 1,379,561,017.25, a significant increase from CNY 702,717,200.36 in the same period of 2021, representing a growth of approximately 96.2%[135]. - The net cash flow from financing activities was positive CNY 479,858,582.24, compared to a negative CNY 197,039,896.09 in the same period of 2021, indicating improved financing conditions[135]. Market Trends and Business Strategy - The growth in operating revenue was primarily driven by increased sales of epidemic prevention materials and new business models during the reporting period[19]. - The company is focusing on diversifying and professionalizing its retail pharmacy services to capture new market share[28]. - The company has expanded its online presence, partnering with major platforms like JD.com, Tmall, and Meituan to enhance B2C and O2O business models, leading to a rapid increase in online order volume[42]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[132]. Risks and Challenges - The company faces risks from industry policy changes, including the impact of "two-invoice system" and "volume-based procurement," which may pressure drug prices and affect retail operations[73]. - The competitive landscape is intensifying, with increased pressure from online medical services and new entrants in the market, necessitating a shift towards "Internet + healthcare" business models[75]. - Financial risks are present due to increased investments in marketing networks and business transformation, which may lead to short-term losses[76]. Shareholder Information - The largest shareholder, Bailian Group Co., Ltd., holds 100,274,734 shares, representing 44.95% of the total shares[116]. - The company has a total of 34,948 ordinary shareholders as of the end of the reporting period[114]. - 百联集团持有第一医药100,274,734股，占公司已发行总股份的44.95%[149]. Compliance and Governance - The company confirmed that it does not belong to any key pollutant discharge units and has not faced any environmental penalties during the reporting period[88]. - The integrity status of the company and its controlling shareholder is good, with no major breaches of trust or unfulfilled court judgments reported[94]. - The company has not received any non-standard audit opinions in the previous annual report, indicating compliance with auditing standards[94]. Financial Reporting - 财务报表符合企业会计准则的要求，真实、完整地反映了公司的财务状况和经营成果[156]. - 合并财务报表的合并范围包括本公司及全部子公司，控制为基础确定[161]. - The company applies the effective interest method for calculating interest on financial assets measured at amortized cost, with gains or losses recognized upon disposal[173].